Ultragenyx Pharmaceutical Inc. Common Stock
RARE IE000KHX9DX6
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -38% | -45% | 5% | -13% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Huizenga Theodore Alan VP |
29.17 USD |
64 Sold |
1,867 USD |
18/09/2025 | 18/09/2025 |
| Parschauer Karah Herdman EX VP |
31.17 USD |
2,450 Sold |
76,367 USD |
12/09/2025 | 12/09/2025 |
| Huizenga Theodore Alan CCO |
31.39 USD |
84 Sold |
2,637 USD |
05/09/2025 | 05/09/2025 |
| Sanders Corazon (corsee) D. |
37.39 USD |
2,405 Sold |
89,923 USD |
20/06/2025 | 20/06/2025 |
| Crombez Eric CMO |
39.24 USD |
520 Sold |
20,405 USD |
21/04/2025 | 05/05/2025 |
| Crombez Eric CMO |
39.24 USD |
520 Sold |
20,405 USD |
21/04/2025 | 05/05/2025 |
| Crombez Eric CMO |
35.11 USD |
242 Sold |
8,497 USD |
21/04/2025 | 21/04/2025 |
| Crombez Eric CMO |
35.11 USD |
242 Sold |
8,497 USD |
21/04/2025 | 21/04/2025 |
| Horn Howard CFO |
40.40 USD |
1,785 Sold |
72,114 USD |
06/03/2025 | 06/03/2025 |
| Kakkis Emil D CEO |
42.10 USD |
73,434 Sold |
3,091,571 USD |
28/02/2025 | 03/03/2025 |